The role of the endothelium during Antibody-mediated rejection: From victim to accomplice

Frontiers in Immunology

Volumn 9, Issue JAN, 2018, Pages

  Cross, Amy Rachael ^a,b   Glotz, Denis ^a,b,c,d   Mooney, Nuala ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Antibody mediated rejection; Donor specific antibodies; Endothelial cells; Inflammation; Transplantation immunology

Indexed keywords

ANTIBODY MEDIATED REJECTION; CELL ACTIVATION; CELL POLARITY; ENDOTHELIUM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; HUMAN; IMMUNOREGULATION; LYMPHOCYTE; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; SHORT SURVEY;

EID: 85041107924     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.00106     Document Type: Short Survey

References (57)

1. Meier-Kriesche H-U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4:378-83. doi:10.1111/j.1600-6143.2004.00332.x
2. Lee P-C, Terasaki PI, Takemoto SK, Lee P-H, Hung C-J, Chen Y-L, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation (2002) 74:1192-4. doi:10.1097/01.TP.0000031249.33030.FB
3. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2012) 12:388-99. doi:10.1111/j.1600-6143.2011.03840.x
4. Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, et al. The Banff2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant (2017) 17:28-41. doi:10.1111/ajt.14107
5. Haas M. The revised (2013) Banffclassification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. Am J Transplant (2016) 16:1352-7. doi:10.1111/ajt.13661
6. Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, et al. The 2013 international society for heart and lung transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2013) 32:1147-62. doi:10.1016/j.healun.2013.08.011
7. Levine DJ, Glanville AR, Aboyoun C, Belperio J, Benden C, Berry GJ, et al. Antibody-mediated rejection of the lung: a consensus report of the international society for heart and lung transplantation. J Heart Lung Transplant (2016) 35:397-406. doi:10.1016/j.healun.2016.01.1223
8. Drachenberg CB, Torrealba JR, Nankivell BJ, Rangel EB, Bajema IM, Kim DU, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banffgrading schema. Am J Transplant (2011) 11:1792-802. doi:10.1111/j.1600-6143.2011.03670.x
9. Aubert O, Loupy A, Hidalgo L, Duong van Huyen J-P, Higgins S, Viglietti D, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol (2017) 28(6):1912-23. doi:10.1681/ASN.2016070797
10. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol (2011) 22:975-83. doi:10.1681/ASN.2010070777
11. Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, et al. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Kidney Int (2017) 92(3):729-42. doi:10.1016/j.kint.2017.03.033
12. Haas M, Mirocha J, Reinsmoen NL, Vo AA, Choi J, Kahwaji JM, et al. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. Kidney Int (2017) 91:729-37. doi:10.1016/j.kint.2016.10.040
13. Issa N, Cosio FG, Gloor JM, Sethi S, Dean PG, Moore SB, et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation (2008) 86:681-5. doi:10.1097/TP.0b013e3181837626
14. Li L, Wadia P, Chen R, Kambham N, Naesens M, Sigdel TK, et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and 'antibodyome' measures. Proc Natl Acad Sci U S A (2009) 106:4148-53. doi:10.1073/pnas.0900563106
15. Cardinal H, Dieudé M, Brassard N, Qi S, Patey N, Soulez M, et al. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant (2013) 13:861-74. doi:10.1111/ajt.12168
16. Delville M, Charreau B, Rabant M, Legendre C, Anglicheau D. Pathogenesis of non-HLA antibodies in solid organ transplantation: where do we stand? Hum Immunol (2016) 77:1055-62. doi:10.1016/j.humimm.2016.05.021
17. Hirohashi T, Uehara S, Chase CM, DellaPelle P, Madsen JC, Russell PS, et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant (2010) 10:510-7. doi:10.1111/j.1600-6143.2009.02958.x
18. Loupy A, Hill GS, Suberbielle C, Charron D, Anglicheau D, Zuber J, et al. Significance of C4d Banffscores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant (2011) 11:56-65. doi:10.1111/j.1600-6143.2010.03364.x
19. Loupy A, Lefaucheur C, Vernerey D, Prugger C, van Huyen J-PD, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 369:1215-26. doi:10.1056/NEJMoa1302506
20. Lion J, Taflin C, Cross AR, Robledo-Sarmiento M, Mariotto E, Savenay A, et al. HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion. Am J Transplant (2016) 16:1408-20. doi:10.1111/ajt.13644
21. Jane-Wit D, Manes TD, Yi T, Qin L, Clark P, Kirkiles-Smith NC, et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells. Circulation (2013) 128:2504-16. doi:10.1161/CIRCULATIONAHA.113.002972
22. Pabois A, Pagie S, Gérard N, Laboisse C, Pattier S, Hulin P, et al. Notch signaling mediates crosstalk between endothelial cells and macrophages via Dll4 and IL6 in cardiac microvascular inflammation. Biochem Pharmacol (2016) 104:95-107. doi:10.1016/j.bcp.2016.01.016
23. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant (2010) 10:1812-22. doi:10.1111/j.1600-6143.2010.03201.x
24. Muczynski KA, Ekle DM, Coder DM, Anderson SK. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol (2003) 14:1336-48. doi:10.1097/01.ASN.0000061778.08085.9F
25. Muczynski KA, Cotner T, Anderson SK. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int (2001) 59:488-97. doi:10.1046/j.1523-1755.2001.059002488.x
26. Cross AR, Lion J, Loiseau P, Charron D, Taupin J-L, Glotz D, et al. Donor specific antibodies are not only directed against HLA-DR: minding your Ps and Qs. Hum Immunol (2016) 77(11):1092-100. doi:10.1016/j.humimm.2016.04.003
27. Hubscher SG, Adams DH, Elias E. Changes in the expression of major histocompatibility complex class II antigens in liver allograft rejection. J Pathol (1990) 162:165-71. doi:10.1002/path.1711620210
28. Suitters A, Rose M, Higgins A, Yacoub MH. MHC antigen expression in sequential biopsies from cardiac transplant patients-correlation with rejection. Clin Exp Immunol (1987) 69:575-83
29. Zhang X, Rozengurt E, Reed EF. HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration. Sci Signal (2010) 3:ra85. doi:10.1126/scisignal.2001158
30. Haylett RS, Koch N, Rink L. MHC class II molecules activate NFAT and the ERK group of MAPK through distinct signaling pathways in B cells. Eur J Immunol (2009) 39:1947-55. doi:10.1002/eji.200838992
31. Al-Daccak R, Mooney N, Charron D. MHC class II signaling in antigen-presenting cells. Curr Opin Immunol (2004) 16:108-13. doi:10.1016/j.coi.2003.11.006
32. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant (2014) 19:33-40. doi:10.1097/MOT.0000000000000040
33. Lepin EJ, Zhang Q, Zhang X, Jindra PT, Hong LS, Ayele P, et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant (2006) 6:1560-71. doi:10.1111/j.1600-6143.2006.01355.x
34. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 352:558-69. doi:10.1056/NEJMoa035717
35. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, Cameron SJ, Bao C, Fox-Talbot K, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A (2007) 104:1301-6. doi:10.1073/pnas.0602035104
36. Fedrigo M, Leone O, Burke MM, Rice A, Toquet C, Vernerey D, et al. Inflammatory cell burden and phenotype in endomyocardial biopsies with antibody-mediated rejection (AMR): a multicenter pilot study from the AECVP. Am J Transplant (2015) 15:526-34. doi:10.1111/ajt.12976
37. Shiao SL, Kirkiles-Smith NC, Shepherd BR, McNiffJM, Carr EJ, Pober JS. Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol (2007) 179:4397-404. doi:10.4049/jimmunol.179.7.4397
38. Taflin C, Favier B, Baudhuin J, Savenay A, Hemon P, Bensussan A, et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A (2011) 108:2891-6. doi:10.1073/pnas.1011811108
39. Deteix C, Attuil-Audenis V, Duthey A, Patey N, McGregor B, Dubois V, et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol (2010) 184:5344-51. doi:10.4049/jimmunol.0902999
40. Louis S, Braudeau C, Giral M, Dupont A, Moizant F, Robillard N, et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation (2006) 81:398-407. doi:10.1097/01.tp.0000203166.44968.86
41. Krustrup D, Madsen CB, Iversen M, Engelholm L, Ryder LP, Andersen CB. The number of regulatory T cells in transbronchial lung allograft biopsies is related to FoxP3 mRNA levels in bronchoalveolar lavage fluid and to the degree of acute cellular rejection. Transpl Immunol (2013) 29:71-5. doi:10.1016/j.trim.2013.08.002
42. Abrahimi P, Qin L, Chang WG, Bothwell ALM, Tellides G, Saltzman WM, et al. Blocking MHC class II on human endothelium mitigates acute rejection. JCI Insight (2016) 1(1):e85293. doi:10.1172/jci.insight.85293
43. Khayyamian S, HutloffA, Büchner K, Gräfe M, Henn V, Kroczek RA, et al. ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci U S A (2002) 99:6198-203. doi:10.1073/pnas.092576699
44. Krupnick AS, Gelman AE, Barchet W, Richardson S, Kreisel FH, Turka LA, et al. Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol (2005) 175:6265-70. doi:10.4049/jimmunol.175.10.6265
45. Riella LV, Watanabe T, Sage PT, Yang J, Yeung M, Azzi J, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant (2011) 11:832-40. doi:10.1111/j.1600-6143.2011.03451.x
46. Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant (2012) 12:313-21. doi:10.1111/j.1600-6143.2011.03836.x
47. Parkes MD, Halloran PF, Hidalgo LG. Evidence for CD16a-mediated NK cell stimulation in antibody-mediated kidney transplant rejection. Transplantation (2017) 101:e102-11. doi:10.1097/TP.0000000000001586
48. Legris T, Picard C, Todorova D, Lyonnet L, Laporte C, Dumoulin C, et al. Antibody-dependent NK cell activation is associated with late kidney allograft dysfunction and the complement-independent alloreactive potential of donor-specific antibodies. Front Immunol (2016) 7:288. doi:10.3389/fimmu.2016.00288
49. Fedrigo M, Feltrin G, Poli F, Frigo AC, Benazzi E, Gambino A, et al. Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection. J Heart Lung Transplant (2013) 32:404-9. doi:10.1016/j.healun.2012.12.017
50. Sellarés J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant (2013) 13:971-83. doi:10.1111/ajt.12150
51. Loupy A, Duong Van Huyen JP, Hidalgo L, Reeve J, Racapé M, Aubert O, et al. Gene expression profiling for the identification and classification of antibody-mediated heart rejection clinical perspective. Circulation (2017) 135:917-35. doi:10.1161/CIRCULATIONAHA.116.022907
52. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 122:787-95. doi:10.1172/JCI59643
53. Valenzuela N, Mulder A, Reed E. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcyRs. J Immunol (2013) 190:1-31. doi:10.4049/jimmunol.1201434.HLA
54. Valenzuela N, Hong L, Shen XD, Gao F, Young SH, Rozengurt E, et al. Blockade of P-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant (2013) 13:299-311. doi:10.1111/ajt.12016.Blockade
55. Valenzuela NM, Trinh KR, Mulder A, Morrison SL, Reed EF. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms. Am J Transplant (2015) 15:1502-18. doi:10.1111/ajt.13174
56. Valenzuela NM, Thomas KA, Mulder A, Parry GC, Panicker S, Reed EF. Complement-mediated enhancement of monocyte adhesion to endothelial cells by HLA antibodies, and blockade by a specific inhibitor of the classical complement cascade, TNT003. Transplantation (2017) 101:1559-72. doi:10.1097/TP.0000000000001486
57. Lion J, Burbach M, Cross A, Poussin K, Taflin C, Kaveri S, et al. Endothelial cell amplification of regulatory T cells is differentially modified by immunosuppressors and intravenous immunoglobulin. Front Immunol (2017) 8:1761. doi:10.3389/fimmu.2017.01761